Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
Mebeverine hydrochloride
Mylan IRE Healthcare Limited
A03AA; A03AA04
Mebeverine hydrochloride
135 milligram(s)
Coated tablet
Product subject to prescription which may be renewed (B)
Synthetic anticholinergics, esters with tertiary amino group; mebeverine
Marketed
1983-02-07
Health Products Regulatory Authority 20 November 2020 CRN00C1LQ Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colofac 135 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Mebeverine Hydrochloride 135mg Excipients with known effect: also includes Lactose monohydrate 97.0 mg per tablet and Sucrose 79.0 mg per tablet. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Coated Tablet. White, circular, sugar coated tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For use in the management of irritable bowel syndrome, (particularly gastrointestinal spasm). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral use. The coated tablets should be swallowed with a sufficient amount of water (at least 100 ml water). They should not be chewed because of the unpleasant taste. Adults and children over 10 years: One tablet three times a day preferably 20 minutes before meals. Duration of use is not limited. However, after a period of several weeks when the desired effect has been obtained, the dosage may be gradually reduced. In case of missed dose(s), the patient should continue with the next dose as prescribed; do not take the missed dose(s) in addition to the regular dose. Children under 10 years: Colofac should not be used in children aged 3 years and younger as no clinical data are available. For children from 3-10 years Colofac 135mg tablets should not be used due to the high content of the active substance. Special Population No posology studies in elderly, renal and/or hepatic impaired patients have been performed. No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients. 4.3 CONTRAINDICATIONS Hypersensitivityto the active substance or to anyof the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Health Products Regulatory Authority 20 November 2020 CRN00C1LQ Page 2 of 5 Baca dokumen lengkapnya